Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Advertisement

Articles by Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Evaluating Tumor Biology in HR+ Metastatic Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
January 29th 2021
  • Prev
  • 1
  • 2
  • Prev
Advertisement


Advertisement
Advertisement

Trending on OncLive

1

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

2

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

3

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

4

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

5

Dr Shah on the Significance of DAYBreak CLL-201 and Bexobrutideg for the CLL Treatment Paradigm

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us